COMPANY

Atavistik Bio

HQ: Cambridge, MA source · atavistikbio.com ↗ · New England

2 open jobs · last seen Oct 23, 2026 · 7 sources

Profile checked Oct 10, 2026

Keywords: Hereditary Hemorrhagic Telangiectasia Osler Weber Rendu Disease Breast Cancer Breast Carcinoma Breast Neoplasms ER Positive Breast Cancer Cervical Cancers Cervical Neoplasms Cervical Carcinoma Triple Negative Breast Cancer Gynecologic Cancers Gynecologic Neoplasm Endometrial Cancer Endometrial Neoplasm Endometrial Carcinoma Fallopian Cancer Ovarian Carcinoma Ovarian Cancer Ovarian Neoplasms Prostate Cancers Prostate Carcinoma Neoplasms by Site Breast Diseases Uterine Neoplasms Female Genital Neoplasms Urogenital Neoplasms ATV-1601

Since the raise (Mar 5, 2026): 2 of 2 open jobs were first seen after it.

2Open jobs $160.0MRaised (2 yrs)2Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Scientist II/Senior Scientist, Biology	Cambridge, MA	Sep 30, 2026	Oct 9, 2026
Sr. Director, Biostatistics	Cambridge, MA	Jun 3, 2026	Oct 9, 2026

See all 2 jobs

Trial and FDA signals

New trial + clinical hiring Started a Phase 1/2 trial (NCT07601425, actual start Jul 27, 2026); 1 clinical-operations role open. ClinicalTrials.gov NCT07601425 (Jul 27, 2026)
Evidence (1 event)
- Jul 27, 2026 · ClinicalTrials.gov NCT07601425
  leadSponsor.name='Atavistik Bio, Inc'; phases=['PHASE1', 'PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-07-27,type:ACTUAL}; studyFirstPostDate=2026-05-22; briefTitle='Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)'

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

Oct 9, 2026 Board tracked Radar started tracking this company’s job board (2 open jobs at last check). source ↗
Sep 24, 2026 Partnership Partnership / licensing: $70M (upfront, as published); deal value up to $1.9B (kept separate from upfront), announced Sep 24, 2026. Source: company's own press page. source ↗
Jul 27, 2026 Trial start Phase 1/Phase 2: Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) source ↗
Mar 5, 2026 Raise Private equity round — Series B Extension: $40M (total, as published), announced Mar 5, 2026. Source: company's own press page. source ↗
Dec 18, 2025 Raise Private equity round — Series B: $120M (total, as published), announced Dec 18, 2025. Source: company's own press page. source ↗
Jul 29, 2025 Trial start 1: A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations source ↗
Jan 2, 2025 Partnership Partnership / licensing announced Jan 2, 2025. Source: company's own press page. source ↗

Upcoming milestones

2027-12 (ESTIMATED) · Phase 1/Phase 2 · Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) · NCT07601425
Aug 31, 2028 (ESTIMATED) · 1 · A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · NCT07038369

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 2

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Scientist II/Senior Scientist, Biology	Cambridge, MA	Sep 30, 2026	Oct 9, 2026	Mid
Sr. Director, Biostatistics	Cambridge, MA	Jun 3, 2026	Oct 9, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $160.0M. Last 2 years.

Mar 5, 2026 Private equity round — Series B Extension: $40M (total, as published), announced Mar 5, 2026. Source: company's own press page. source ↗
Dec 18, 2025 Private equity round — Series B: $120M (total, as published), announced Dec 18, 2025. Source: company's own press page. source ↗
Sep 24, 2026 Partnership / licensing: $70M (upfront, as published); deal value up to $1.9B (kept separate from upfront), announced Sep 24, 2026. Source: company's own press page. source ↗
Jan 2, 2025 Partnership / licensing announced Jan 2, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07601425	Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)	Phase 1/Phase 2	Recruiting	Jul 27, 2026	2027-12 (estimated)
NCT07038369	A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations	1	Active, not recruiting	Jul 29, 2025	Aug 31, 2028 (estimated)

Connect

See your connections at Atavistik Bio on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18